Wylie, TX, United States

Don't Obsess Over 2027 on China

Numerology is a potent force in human affairs. So is a deadline—especially when it’s clear fateful consequences will come to pass once the cutoff date arrives. The wry English wit Dr. Samuel Johnson was on to something when he quipped that “when a man knows h…

2025-01-06 18:11

Winning Ways with Western Dressage to Host Record Eleven Winning Weekends in 2025

With the expertise of Lynn Palm as judge, instructor and coach along with partner Marie-Frances Davis’ background in event management, the pair continues their Winning Ways with Western Dressage into 2025. Beginning in 2022 with two locations, the first ever …

2024-12-27 16:48

U.S. Naval Strategy and Fleet Design for the Twenty-First Century

So it appears the congressionally mandated National Commission on the Future of the Navy has commenced work at long last. As Breaking Defense recalls, the Fiscal Year 2023 National Defense Authorization Act instituted the eight-member commission to “undertake…

2024-12-21 19:02

Volt Lithium Scales-Up U.S. Field Operations in Texas, Paving Way for Significant Growth in 2025

VOLT LITHIUM SCALES-UP U.S. FIELD OPERATIONS IN TEXAS, PAVING WAY FOR SIGNIFICANT GROWTH IN 2025 ......

2024-12-18 08:05

Why the U.S. Navy Must Fight Rust as Hard as Rivals

Pop quiz: look at this photograph of USS Green Bay (LPD 20), one of the U.S. Navy’s premier amphibious transports, making port in Pearl Harbor late last month. Now look at Green Bay’s rust-streaked hull through the eyes of a friend or foe of America. Will suc…

2024-12-10 15:03

Volt Lithium and Wellspring Hydro Enter Into a Field Study Agreement Backed by a Grant from the State of North Dakota to Extract Lithium from Bakken Oilfield Brine

VOLT LITHIUM AND WELLSPRING HYDRO ENTER INTO A FIELD STUDY AGREEMENT BACKED BY A GRANT FROM THE STATE OF NORTH DAKOTA ......

2024-12-10 08:05

Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML

Basel, December 8, 2024 – Novartis today announced positive, longer-term results from the pivotal Phase III ASC4FIRST trial with Scemblix® (asciminib) showing superior major molecular response (MMR) rates at week 961. The study compared the MMR rate of Scembl…

2024-12-08 17:30